Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 0 · FY2024 0
Real-estate / development arm associated with the MedLog Georgia pharma-logistics group.
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|
| Total Revenue | 61 | 4,170 | 4,599 | 6,717 | 9,481 | 10,718 | nmf |
| Total COGS | 11 | 2,408 | 3,114 | 4,657 | 5,444 | 8,449 | nmf |
| Gross Profit | 50 | 1,762 | 1,485 | 2,059 | 4,036 | 2,270 | +114.9% |
| Gross Margin | 81.8% | 42.3% | 32.3% | 30.7% | 42.6% | 21.2% | |
| 80 | 646 | 789 | 1,031 | 1,843 | 1,761 | +85.5% | |
| EBITDA | 31 | 1,116 | 696 | 1,028 | 2,193 | 509 | nmf |
| EBITDA Margin | 50.4% | 26.8% | 15.1% | 15.3% | 23.1% | 4.8% | |
| Total D&A | 0 | 27 | 31 | 55 | 78 | 132 | +49.1% |
| EBIT / Operating Income | 31 | 1,089 | 666 | 973 | 2,115 | 377 | nmf |
| Total Interest Income | 250 | 25 | 21 | 32 | 119 | 52 | -26.9% |
| Total Interest Expense | 0 | 884 | 185 | 370 | 488 | 728 | -4.8% |
| 0 | 23 | 27 | 144 | 260 | 29 | +6.3% | |
| Profit Before Tax | 220 | 206 | 528 | 779 | 2,006 | 328 | nmf |
| Total Income Tax | 0 | 9 | 0 | 0 | 0 | 0 | |
| Net Profit / (Loss) | 220 | 145 | 470 | 695 | 2,006 | 470 | nmf |
| Net Margin | 362.7% | 3.5% | 10.2% | 10.3% | 21.2% | 4.4% | |
| Other Comprehensive Income | 0 | 0 | 3,895 | 55 | 1,172 | 1,088 | -34.6% |
| Total Comprehensive Income | 220 | 145 | 4,365 | 749 | 3,178 | 618 | +23.0% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →